Page last updated: 2024-08-26

carbidopa, levodopa drug combination and Parkinson Disease, Secondary

carbidopa, levodopa drug combination has been researched along with Parkinson Disease, Secondary in 32 studies

Research

Studies (32)

TimeframeStudies, this research(%)All Research%
pre-19908 (25.00)18.7374
1990's13 (40.63)18.2507
2000's3 (9.38)29.6817
2010's5 (15.63)24.3611
2020's3 (9.38)2.80

Authors

AuthorsStudies
Guerrero, MF; López, JL; Olaya, MDP; Vergel, NE; Viña, MD1
Balogun, CI; Fatoki, AM; Oladimeji, S; Olofinnade, AT; Onaolapo, AY; Onaolapo, OJ; Onaolapo, TM1
Bolia, R; Panda, PK; Sharawat, IK; Shrivastava, Y1
Azandeh, SS; Farbood, Y; Ghasemi Dehcheshmeh, M; Jalali, MS; Mansouri, E; Saki, G; Sarkaki, A1
Chang, MC; Chun, MH; Kang, CG; Kong, EJ1
Brauer, AF; Ciucci, MR; Kelm-Nelson, CA1
Arami, MA; Ayromlou, H; Najmi, S1
Ahmad, M; Gupta, A; Rizvi, I; Zaidi, N1
Borra, S; Hauser, RA; Zesiewicz, TA1
Delville, Y; Fleming, SM; Schallert, T1
Kamenetskiĭ, VK1
Lang, AE1
Lunn, V; Northcott, C; Yatham, LN1
Caligiuri, MP1
Bankiewicz, KS; de Jesus, S; Sheng, J; Takubo, H; Thomas, J; Wang, J1
Bédard, PJ; Blanchette, P; DiPaolo, T; Falardeau, P; Gagnon, C; Gomez-Mancilla, B1
Eller, RV; Gash, DM; Greenamyre, JT; Kurlan, R; Ovadia, A; Zhang, Z1
Emerich, DF; Francis, JM; Lindner, MD; Plone, MA1
Blaney, TJ; Chandonait, SE; Emerich, DF; Lindner, MD; Mullins, TD; Plone, MA; Sherman, SS; Stott, JA; Winn, SR1
Collins, F; Gash, DM; Hilt, D; Kryscio, R; Lapchak, PA; Lebel, C; Miyoshi, Y; Ovadia, A; Zhang, Z1
Golubev, VL; Shtul'man, DR; Shvareva, IS; Veĭn, AM; Zhuchenko, TD1
Lapchak, PA1
Ahlskog, JE1
Bankiewicz, KS; Bringas, J; Budinger, TF; Cunningham, J; Eberling, JL; Harvey-White, J; Jagust, W; Kohutnicka, M; Pivirotto, P1
Gash, DM; Kim, MH; Kurlan, R1
Critchley, P; Grandas, F; Marsden, CD; Quinn, N; Rohan, A; Stahl, SM1
Jankovic, J1
Bioulac, B; Doudet, D; Gross, C; Lebrun-Grandié, P2
Brown, RG; Gotham, AM; Marsden, CD; Nissenbaum, H; Quinn, NP; Toone, B1
Duvoisin, RC; Sage, JI1
Luque, FA; Petruska, P; Selhorst, JB1

Reviews

4 review(s) available for carbidopa, levodopa drug combination and Parkinson Disease, Secondary

ArticleYear
Hemiatrophy, juvenile-onset exertional alternating leg paresis, hypotonia, and hemidystonia and adult-onset hemiparkinsonism: the spectrum of hemiparkinsonism-hemiatrophy syndrome.
    Movement disorders : official journal of the Movement Disorder Society, 1995, Volume: 10, Issue:4

    Topics: Antiparkinson Agents; Blood Glucose; Carbidopa; Contrast Media; Deoxyglucose; Dihydroxyphenylalanine; Dominance, Cerebral; Drug Combinations; Female; Fluorodeoxyglucose F18; Functional Laterality; Hemiplegia; Humans; Levodopa; Middle Aged; Muscle Hypotonia; Muscular Atrophy; Neurologic Examination; Parkinson Disease, Secondary; Physical Exertion; Substantia Nigra; Tomography, Emission-Computed

1995
A preclinical development strategy designed to optimize the use of glial cell line-derived neurotrophic factor in the treatment of Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 1998, Volume: 13 Suppl 1

    Topics: Animals; Antiparkinson Agents; Carbidopa; Corpus Striatum; Dopamine; Drug Combinations; Drug Evaluation, Preclinical; Drug Therapy, Combination; Glial Cell Line-Derived Neurotrophic Factor; Humans; Levodopa; Nerve Growth Factors; Nerve Regeneration; Nerve Tissue Proteins; Neuroglia; Neuronal Plasticity; Parkinson Disease, Secondary; Substantia Nigra; Tyrosine 3-Monooxygenase

1998
Medical treatment of later-stage motor problems of Parkinson disease.
    Mayo Clinic proceedings, 1999, Volume: 74, Issue:12

    Topics: Amantadine; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Cholinergic Antagonists; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Combinations; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Nitrophenols; Parkinson Disease, Secondary; Propranolol; Randomized Controlled Trials as Topic; Selegiline; Tolcapone

1999
Parkinson's disease: recent advances in therapy.
    Southern medical journal, 1988, Volume: 81, Issue:8

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Medulla; Antiparkinson Agents; Carbidopa; Dopamine; Drug Administration Schedule; Drug Combinations; Humans; Levodopa; Middle Aged; Parkinson Disease; Parkinson Disease, Secondary; Pyridines

1988

Other Studies

28 other study(ies) available for carbidopa, levodopa drug combination and Parkinson Disease, Secondary

ArticleYear
Coumarin analogue 3-methyl-7H-furo[3,2-g] chromen-7-one as a possible antiparkinsonian agent
    Biomedica : revista del Instituto Nacional de Salud, 2019, 09-01, Volume: 39, Issue:3

    Topics: Animals; Antiparkinson Agents; Carbidopa; Catalepsy; Coumarins; Disease Models, Animal; Drug Combinations; Drug Evaluation, Preclinical; Haloperidol; Levodopa; Locomotion; Male; Mice; Mice, Inbred ICR; Monoamine Oxidase Inhibitors; Parkinson Disease, Secondary; Reserpine

2019
An Evaluation of the Effects of Pyridoxal Phosphate in Chlorpromazineinduced Parkinsonism using Mice.
    Central nervous system agents in medicinal chemistry, 2020, Volume: 20, Issue:1

    Topics: Animals; Antioxidants; Antiparkinson Agents; Antipsychotic Agents; Behavior, Animal; Body Weight; Carbidopa; Chlorpromazine; Diet; Drug Combinations; Eating; Grooming; Levodopa; Lipid Peroxidation; Mice; Motor Activity; Parkinson Disease, Secondary; Pyridoxal Phosphate

2020
Case Report: Dengue Virus-Triggered Parkinsonism in an Adolescent.
    The American journal of tropical medicine and hygiene, 2020, Volume: 103, Issue:2

    Topics: Adolescent; Antiparkinson Agents; Brain; Carbidopa; Dengue; Diffusion Magnetic Resonance Imaging; Drug Combinations; Electroencephalography; Humans; India; Levodopa; Magnetic Resonance Imaging; Male; Parkinson Disease, Secondary; Treatment Outcome

2020
Therapeutic effects of Wharton's jelly-derived Mesenchymal Stromal Cells on behaviors, EEG changes and NGF-1 in rat model of the Parkinson's disease.
    Journal of chemical neuroanatomy, 2021, Volume: 113

    Topics: Animals; Antiparkinson Agents; Behavior, Animal; Carbidopa; Dopaminergic Neurons; Drug Combinations; Electroencephalography; Insulin-Like Growth Factor I; Levodopa; Male; Medial Forebrain Bundle; Mesenchymal Stem Cell Transplantation; Motor Activity; Nerve Growth Factor; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Wistar; Substantia Nigra; Wharton Jelly

2021
Parkinsonism after external ventricular drainage in a patient with intraventricular hemorrhage.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2015, Volume: 24, Issue:3

    Topics: Activities of Daily Living; Carbidopa; Caudate Nucleus; Cerebral Ventricles; Drainage; Drug Combinations; Female; Humans; Intracranial Hemorrhages; Levodopa; Magnetic Resonance Imaging; Middle Aged; Parkinson Disease, Secondary; Positron-Emission Tomography; Predictive Value of Tests; Putamen; Radiopharmaceuticals; Recovery of Function; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Tropanes; Ventriculoperitoneal Shunt

2015
Vocal training, levodopa, and environment effects on ultrasonic vocalizations in a rat neurotoxin model of Parkinson disease.
    Behavioural brain research, 2016, 07-01, Volume: 307

    Topics: Animals; Antiparkinson Agents; Apomorphine; Carbidopa; Communication Disorders; Disease Models, Animal; Dopamine; Dopamine Agonists; Drug Combinations; Fourier Analysis; Levodopa; Male; Neurotoxins; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Long-Evans; Stereotyped Behavior; Time Factors; Ultrasonics; Vocalization, Animal

2016
Hemiparkinsonism-hemiatrophy syndrome.
    Archives of Iranian medicine, 2011, Volume: 14, Issue:2

    Topics: Adult; Antiparkinson Agents; Atrophy; Benzothiazoles; Biperiden; Carbidopa; Cerebral Cortex; Cerebral Ventricles; Dopamine Agonists; Drug Combinations; Humans; Indans; Levodopa; Magnetic Resonance Imaging; Male; Monoamine Oxidase Inhibitors; Parkinson Disease, Secondary; Pramipexole; Tomography, X-Ray Computed

2011
Isolated extra pontine myelinolysis presenting as acute onset parkinsonism.
    BMJ case reports, 2012, Oct-12, Volume: 2012

    Topics: Acute Disease; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Hyponatremia; Levodopa; Magnetic Resonance Imaging; Middle Aged; Myelinolysis, Central Pontine; Parkinson Disease, Secondary; Saline Solution, Hypertonic

2012
Clozapine withdrawal symptoms in a Parkinson's disease patient.
    Movement disorders : official journal of the Movement Disorder Society, 2002, Volume: 17, Issue:6

    Topics: Aged; Antipsychotic Agents; Carbidopa; Clozapine; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Hallucinations; Humans; Levodopa; Male; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Substance Withdrawal Syndrome

2002
An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate.
    Behavioural brain research, 2005, Jan-30, Volume: 156, Issue:2

    Topics: Animals; Antiparkinson Agents; Behavior, Animal; Carbidopa; Cell Count; Differential Threshold; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Immunohistochemistry; Levodopa; Male; Methylphenidate; Motor Activity; Movement; Nerve Degeneration; Neurons; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Rats; Rats, Long-Evans; Rotarod Performance Test; Substantia Nigra; Tyrosine 3-Monooxygenase

2005
[Treatment of patients with vascular parkinsonism with the preparations nakom and madopar].
    Klinicheskaia meditsina, 1984, Volume: 62, Issue:4

    Topics: Adult; Aged; Antiparkinson Agents; Benserazide; Carbidopa; Drug Combinations; Humans; Hydrazines; Levodopa; Middle Aged; Parkinson Disease, Secondary

1984
Parkinsonism and bipolar affective disorder.
    Canadian journal of psychiatry. Revue canadienne de psychiatrie, 1995, Volume: 40, Issue:3

    Topics: Aged; Antiparkinson Agents; Bipolar Disorder; Carbidopa; Clonazepam; Dopamine; Drug Combinations; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Lithium Carbonate; Male; Parkinson Disease, Secondary

1995
Portable device for quantifying parkinsonian wrist rigidity.
    Movement disorders : official journal of the Movement Disorder Society, 1994, Volume: 9, Issue:1

    Topics: Adult; Aged; Antiparkinson Agents; Antipsychotic Agents; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Muscle Rigidity; Muscle Tonus; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Psychotic Disorders; Risk Factors; Transducers

1994
A 6-hydroxydopamine-induced selective parkinsonian rat model: further biochemical and behavioral characterization.
    Experimental neurology, 1994, Volume: 126, Issue:2

    Topics: Amphetamine; Animals; Brain; Carbidopa; Caudate Nucleus; Corpus Striatum; Dopamine; Drug Combinations; Functional Laterality; Immunohistochemistry; Levodopa; Male; Mesencephalon; Models, Neurological; Motor Activity; Nucleus Accumbens; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Rotation; Tyrosine 3-Monooxygenase

1994
Role of selective D1 and D2 agonists in inducing dyskinesia in drug-naive MPTP monkeys.
    Advances in neurology, 1993, Volume: 60

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Brain Mapping; Carbidopa; Corpus Striatum; Dopamine Agents; Dose-Response Relationship, Drug; Down-Regulation; Drug Combinations; Dyskinesia, Drug-Induced; Female; Levodopa; Locomotion; Macaca fascicularis; Parkinson Disease, Secondary; Psychomotor Performance; Receptors, Dopamine D1; Receptors, Dopamine D2

1993
Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease.
    Annals of neurology, 1994, Volume: 35, Issue:6

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetamides; Analysis of Variance; Animals; Anticonvulsants; Antiparkinson Agents; Brain; Carbidopa; Dizocilpine Maleate; Dose-Response Relationship, Drug; Drug Combinations; Levodopa; Macaca mulatta; Male; Motor Activity; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Reserpine; Time Factors

1994
Validation of a rodent model of Parkinson's Disease: evidence of a therapeutic window for oral Sinemet.
    Brain research bulletin, 1996, Volume: 39, Issue:6

    Topics: Administration, Oral; Animals; Antiparkinson Agents; Carbidopa; Dose-Response Relationship, Drug; Drug Combinations; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; Levodopa; Male; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Stereotyped Behavior

1996
Somatic delivery of catecholamines in the striatum attenuate parkinsonian symptoms and widen the therapeutic window of oral sinemet in rats.
    Experimental neurology, 1997, Volume: 145, Issue:1

    Topics: Administration, Oral; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Carbidopa; Cell Transplantation; Disease Models, Animal; Dopamine; Drug Combinations; Drug Synergism; Levodopa; Male; Movement Disorders; Neostriatum; Parkinson Disease, Secondary; PC12 Cells; Rats; Rats, Sprague-Dawley; Rotation

1997
Glial cell line-derived neurotrophic factor-levodopa interactions and reduction of side effects in parkinsonian monkeys.
    Annals of neurology, 1997, Volume: 42, Issue:2

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Carbidopa; Cerebral Ventricles; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Female; Glial Cell Line-Derived Neurotrophic Factor; Injections, Intraventricular; Levodopa; Macaca mulatta; Motor Activity; Nerve Growth Factors; Nerve Tissue Proteins; Neuroprotective Agents; Parkinson Disease, Secondary; Stereotyped Behavior

1997
[Vascular parkinsonism].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 1998, Volume: 98, Issue:4

    Topics: Antiparkinson Agents; Brain Ischemia; Carbidopa; Drug Combinations; Electroencephalography; Female; Follow-Up Studies; Humans; Levodopa; Magnetic Resonance Imaging; Middle Aged; Parkinson Disease, Secondary; Ultrasonography, Doppler, Transcranial

1998
Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach.
    Experimental neurology, 2000, Volume: 164, Issue:1

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Aromatic-L-Amino-Acid Decarboxylases; Carbidopa; Catheterization; Caudate Nucleus; Cell Line; Dependovirus; Dopamine; Drug Administration Routes; Drug Combinations; Fluorine Radioisotopes; Genetic Therapy; Genetic Vectors; Levodopa; Macaca mulatta; Magnetic Resonance Imaging; Neurons; Parkinson Disease, Secondary; Prodrugs; Putamen; Tomography, Emission-Computed; Tyrosine; Tyrosine 3-Monooxygenase

2000
Oral levodopa dose-response study in MPTP-induced hemiparkinsonian monkeys: assessment with a new rating scale for monkey parkinsonism.
    Movement disorders : official journal of the Movement Disorder Society, 1991, Volume: 6, Issue:2

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Antiparkinson Agents; Carbidopa; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Combinations; Levodopa; Macaca mulatta; Neurologic Examination; Parkinson Disease, Secondary; Stereotyped Behavior

1991
Antiparkinsonian activity of a single oral dose of PHNO.
    Movement disorders : official journal of the Movement Disorder Society, 1987, Volume: 2, Issue:1

    Topics: Administration, Oral; Adult; Aged; Carbidopa; Dopamine Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Oxazines; Parkinson Disease, Secondary; Reaction Time

1987
[A model of Parkinson's disease: effect of L-dopa therapy on movement parameters and electromyographic activity in monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)].
    Comptes rendus des seances de la Societe de biologie et de ses filiales, 1985, Volume: 179, Issue:1

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Carbidopa; Disease Models, Animal; Drug Combinations; Electromyography; Levodopa; Macaca mulatta; Movement Disorders; Parkinson Disease, Secondary; Pyridines

1985
Mood swings associated with the 'on-off' phenomenon in Parkinson's disease.
    Psychological medicine, 1987, Volume: 17, Issue:4

    Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Depressive Disorder; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Mood Disorders; Parkinson Disease; Parkinson Disease, Secondary

1987
Effect of increasing regimens of levodopa on chronic MPTP-induced parkinsonism in monkey; mechanographic and electromyographic data.
    Electromyography and clinical neurophysiology, 1986, Volume: 26, Issue:8

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Carbidopa; Dose-Response Relationship, Drug; Drug Combinations; Electromyography; Levodopa; Macaca mulatta; Parkinson Disease, Secondary; Pyridines

1986
Sudden onset of confusion with severe exacerbation of parkinsonism during levodopa therapy.
    Movement disorders : official journal of the Movement Disorder Society, 1986, Volume: 1, Issue:4

    Topics: Aged; Carbidopa; Cognition Disorders; Confusion; Dose-Response Relationship, Drug; Drug Combinations; Humans; Levodopa; Male; Parkinson Disease, Secondary

1986
Parkinsonism induced by high-dose cytosine arabinoside.
    Movement disorders : official journal of the Movement Disorder Society, 1987, Volume: 2, Issue:3

    Topics: Carbidopa; Cytarabine; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Leukemia, Myelomonocytic, Acute; Levodopa; Middle Aged; Parkinson Disease, Secondary

1987